Taro Company Profile
What is the competitive landscape for TARO
TARO has one hundred and twenty-nine approved drugs.
There are two US patents protecting TARO drugs. There is one tentative approval on TARO drugs.
Summary for Taro
| US Patents: | 2 |
| Tradenames: | 91 |
| Ingredients: | 80 |
| NDAs: | 129 |
| Patent Litigation for Taro: | See patent lawsuits for Taro |
| PTAB Cases with Taro as petitioner: | See PTAB cases with Taro as petitioner |
Drugs and US Patents for Taro
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taro | ENALAPRIL MALEATE | enalapril maleate | TABLET;ORAL | 075657-003 | Jan 23, 2001 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro | POTASSIUM CHLORIDE | potassium chloride | SOLUTION;ORAL | 218960-001 | Jul 22, 2025 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro | ILOPERIDONE | iloperidone | TABLET;ORAL | 207098-005 | Jul 22, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Taro | WARFARIN SODIUM | warfarin sodium | TABLET;ORAL | 040301-002 | Jul 15, 1999 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro | PERAMPANEL | perampanel | TABLET;ORAL | 209538-005 | Nov 25, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro | OXCARBAZEPINE | oxcarbazepine | TABLET;ORAL | 077801-002 | Nov 15, 2007 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro | FLUOCINONIDE EMULSIFIED BASE | fluocinonide | CREAM;TOPICAL | 072494-001 | Jan 19, 1989 | AB2 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Taro
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Taro | OVIDE | malathion | LOTION;TOPICAL | 018613-001 | Aug 2, 1982 | 7,977,324 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TARO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Lotion | 0.5% | ➤ Subscribe | 2011-03-16 |
| ➤ Subscribe | Topical Spray | 0.25% | ➤ Subscribe | 2013-12-18 |
International Patents for Taro Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007005988 | ⤷ Start Trial |
| Japan | 5474347 | ⤷ Start Trial |
| Japan | 2013032405 | ⤷ Start Trial |
| Brazil | PI0612686 | ⤷ Start Trial |
| China | 101287374 | ⤷ Start Trial |
| Japan | 2009500422 | ⤷ Start Trial |
| Canada | 2612578 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Taro Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1620113 | C01620113/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: IVERMECTINUM; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 65561 20.12.2016 |
| 0663828 | C300085 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| 2666774 | CA 2020 00037 | Denmark | ⤷ Start Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 2673237 | 201940014 | Slovenia | ⤷ Start Trial | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1173; DATE OF NATIONAL AUTHORISATION: 20180322; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 2435024 | SPC/GB21/029 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210 |
| 2435024 | 2190014-7 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210 |
| 1441735 | SPC/GB08/020 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
